Fig. 2: Mdivi-1 mediates MHC-I expression in syngeneic tumor models.

A Tumor volume measurements after subcutaneous implantation, arrow indicates the time of Mdivi-1 or DMSO treatment (mean ± s.e.m; n = 6; p = 0.0124; **p < 0.001 by two-way ANOVA followed by Dunnett’s tests for multiple comparisons). B Weights of harvested tumors (n = 6; p < 0.001; **p < 0.001 by two-tailed t-test). C Photograph of harvested tumors. D Membrane expression of H-2K^b and SIINFEKL-H-2K^b complex of isolated primary cancer cells from harvested tumors by flow cytometry (mean ± s.e.m; n = 5; p < 0.0001 for H-2K^b and SIINFEKL-H-2K^b complex; **p < 0.001 by two-tailed t-test). E IFN-γ-producing CTLs as quantified by ELISpot (mean ± s.e.m; n = 6; p < 0.0001; **p < 0.001 by two-tailed t-test). F The isolated tumor-infiltrated CD8⁺ T cells were stained with anti-OVA-H-2K^b tetramer and anti-CD8a, and the percentages of infiltrated OVA-specific CTLs were quantified by flow cytometry (mean ± s.e.m; n = 3; p = 0.0012; *p < 0.01 by two-tailed t-test). G Biodistribution of cancer cells 12 and 25 days after inoculation (n = 6). Color scales represent photon intensities. H Kaplan–Meier survival curve was plotted for tail vein tumor inoculation model, and survival difference was analyzed using log-rank test (n = 6; p = 0.0012).